BioSpace News Archive

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced record results in its technology service revenues, demonstrating a continued pattern of improved growth for its first fiscal quarter ending June 30, 2020.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the appointment of Fouad Namouni, M.D., as President, Research & Development, effective September 1, 2020.

Laborie Medical Technologies (LABORIE), a leading diagnostic and therapeutic medical technology company, in partnership with Signet Healthcare Partners, a growth equity firm specializing in healthcare investments, signed an agreement to acquire GI Supply,

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in September:

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced Dr. Stefanie Johns, who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled to appear as a featured guest on One America News Network Tuesday, September 1, 2020 at 3:00pm ET.

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in the Morgan Stanley Virtual Healthcare Conference on Wednesday, September 16, 2020.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in September:

Hereditary cancers are caused by gene mutations that people are born with; passed down to them from either their mother or their father. According to many medical research report, between 5% and 10% of many common cancers are considered hereditary.

Transparency Market Research has published a new report on the Soft tissue allografts market for the forecast period of 2019–2027.

According to the Food and Drug Administration (FDA), direct-to-consumer laboratory tests are diagnostic tests marketed directly to consumers without the involvement of a health care provider